ReviewDrug safety2003
Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant?
Review in Drug safety, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 55 citations in OpenAlex.
- Drug interaction potential of Ankaferd blood stopper® in human hepatocarcinoma cells.Turkish journal of medical sciences · 2023Article
- Severe Rhabdomyolysis as Complication of Interaction between Atorvastatin and Fusidic Acid in a Patient in Lifelong Antibiotic Prophylaxis: A Dangerous Combination.Case reports in medicine · 2016Article
- Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health Transition.Pharmaceuticals (Basel, Switzerland) · 2015Article
- Pharmacokinetic drug-drug interaction and their implication in clinical management.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2013Review
- Rhabdomyolysis caused by an unusual interaction between azithromycin and simvastatin.Journal of cardiovascular disease research · 2012Article
- Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.Clinical pharmacokinetics · 2010Review
- Statins and congestive heart failure.Current atherosclerosis reports · 2008Review
- Rhabdomyolysis updated.Hippokratia · 2007Article
- Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins.Drugs & aging · 2007Article
- Pharmacokinetic interactions with thiazolidinediones.Clinical pharmacokinetics · 2007Review
- Pharmacokinetic drug interaction profiles of proton pump inhibitors.Drug safety · 2006Review
- Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.Drug safety · 2006Review
- Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update.Drug safety · 2005Review
- Early detection of drug interactions utilizing a computerized drug prescription handling system-focus on cerivastatin-gemfibrozil.European journal of clinical pharmacology · 2004Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present review outlines the clinical relevance of pharmacokinetic drug interactions within the HMG-CoA reductase inhibitor class. These interactions can result in markedly increased or decreased plasma concentrations of some drugs within this class. However, the relationship between altered plasma concentrations and adverse effects or toxicity may not be linear. It is likely that other variables affect this concentration-effect relationship including: rapid changes in the concentration, concomitant lipid-lowering therapy or host genetic factors that code for different forms or amounts of metabolising enzymes and drug receptors. It is not currently possible to predict which patients will manifest clinically important drug-drug interactions, nor what concentration of an HMG-CoA reductase inhibitor will cause rhabdomyolysis. Thus, until prescribers have better scientific information from which to develop a 'therapeutic range' for each agent, caution should be exercised. In particular, patients taking a CYP3A4-metabolised agent, e.g. atorvastatin, simvastatin and lovastatin, should not be started on a CYP3A4 inhibitor or inducer without close monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.